Multiple innovations have leveraged artificial intelligence to accelerate drug discovery pipelines and RNA vaccine design. Researchers at MIT utilized generative AI to design novel antibiotic candidates effective against resistant bacterial strains, generating millions of virtual compounds with new mechanisms of action. Separately, MIT teams harnessed AI to optimize lipid nanoparticle delivery systems, enhancing RNA vaccine and therapeutic efficacy. Additionally, novel machine learning models were developed for chemical compound analysis, promising to fast-track pharmaceutical development processes.